A new £38m National Biologics Manufacturing Centre is to be located in the North East.
The Centre for Process Innovation (CPI) has announced that its new National Biologics Manufacturing Centre will be in Darlington.
David Willetts, minister for universities and science, said: “The new National Biologics Manufacturing Centre will significantly increase the UK’s manufacturing capability in biologics, keeping us ahead in the global race and strengthening the UK’s position as the location of choice for life sciences companies.”
The flagship centre, which forms part of CPI, will help companies of all sizes in the biologics market to develop, prove, demonstrate, scale up and ultimately commercialise new biologics process technologies.
Biologics are therapeutic proteins manfactured from living cells.
The centre is part of the Government’s Strategy for Life Science and will help UK companies to develop a competitive foothold in the growing global biopharmaceutical market.
Darlington was chosen for its transport links, particularly the East Coast Mainline, close proximity to existing pharmaceutical companies and relevant universities in the north of England in addition to growth opportunities within the Tees Valley Enterprise Zone.
Bill Dixon, leader of Darlington City Council, said: “We are delighted that CPI has chosen Darlington to be the location of this new national centre. The location of the centre in North East England will attract further investment, talent and opportunities for the region to play a role in the development and commercialisation of pharmaceuticals into the global marketplace.”